IRLAB Therapeutics, a Gothenburg, Sweden-based company dedicated to discovering and developing novel treatments for Parkinson’s disease, has announced its upcoming participation in IBAGS XIV, the triennial meeting in Stockholm, Sweden. IRLAB’s Director of Biology Daniel Andersson will present the abstract “ISP – a phenotypic and translational approach for drug discovery in basal ganglia-related disorders”. This groundbreaking approach will demonstrate the potential of IRLAB as a leader in the development of effective therapies for Parkinson’s disease.
At the upcoming event, D.R. Andersson, S. Oleszko, E. Werner, S. Waters, C. Sonesson, P. Svensson, N. Waters from IRLAB will be showcasing their novel research on an innovative phenotypic and translational approach for drug discovery in basal ganglia-related disorders.
Through a poster presentation, their abstract titled “ISP – a phenotypic and translational approach for drug discovery in basal ganglia-related disorders” promises to spark thoughtful discussion among experts in the field. Come join us to find out more about this exciting breakthrough!
The XIV Triennial Meeting of the IBAGS is an invaluable event which brings together renowned scientists from all corners of the globe, coming together with one common goal;to discover more about the basal ganglia of the brain and the disorders of basal ganglia origin such as Parkinson’s disease, Huntington’s disease, obsessive-compulsive disorders, depression, schizophrenia, and drug addiction. With over 350-400 researchers collaborating with a variety of advanced research techniques for the molecular, cellular, system-level investigations and animal behavior, join us in our mission to uncover the mystery of the brain’s basal ganglia.